Merck's Gardasil gets positive opinion from European Medicines Agency

By Elaine Rigoli

Tampa, Fla., July 28 - Merck & Co., Inc.'s Gardasil (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine) has received a positive opinion from the Committee for Medicinal Products for Human Use in Europe.

The opinion recommends that Gardasil be approved to immunize children and adolescents aged nine to 15 years and females aged 16 to 26 years for the prevention of cervical cancer, high-grade cervical dysplasia, high-grade vulvar dysplastic lesions and external genital warts caused by human papillomavirus types 6, 11, 16 and 18.

Following the review, the opinion for Gardasil is transmitted to the European Commission for final approval.

Merck, located in Whitehouse Station, N.J., is a global pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.